Reply by the authors
Urology
.
2014 Aug;84(2):495-6.
doi: 10.1016/j.urology.2014.04.004.
Authors
Jonathan Jarow
1
,
Paul G Kluetz
1
,
Seth P Lerner
2
,
Ke Liu
3
,
Rajeshwari Sridhara
4
,
Dean Bajorin
5
,
Sam Chang
6
,
Colin P N Dinney
7
,
Susan Groshen
8
,
Ronald A Morton
9
,
Michael O'Donnell
10
,
Diane Zipursky Quale
11
,
Mark Schoenberg
12
,
John Seigne
13
,
Bhadrasain Vikram
14
Affiliations
1
Office of Hematology and Oncology Products, U.S. Food and Drug Administration, Silver Spring, MD.
2
Scott Department of Urology, Baylor College of Medicine Medical Center, Houston, TX.
3
Office of Cellular, Tissue and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD.
4
Division of Biometrics V, Office of Biostatistics, CDER, Food and Drug Administration, Silver Spring, MD.
5
Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY.
6
Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN.
7
The University of Texas MD Anderson Cancer Center, Houston, TX.
8
Department of Preventive Medicine, USC Norris Comprehensive Cancer Center, USC/Keck School of Medicine, Los Angeles, CA.
9
American Medical Systems, Minnetonka, MN.
10
University of Iowa, Iowa city, IA.
11
Bladder Cancer Advocacy Network, Bethesda, MD.
12
The Johns Hopkins University School of Medicine, Baltimore, MD.
13
Dartmouth-Hitchcock Medical Center and Norris Cotton Cancer Center, Lebanon, NH.
14
National Cancer Institute, Bethesda, MD.
PMID:
25065996
DOI:
10.1016/j.urology.2014.04.004
No abstract available
Publication types
Letter
Comment
MeSH terms
Clinical Trials as Topic / methods*
Humans
Urinary Bladder Neoplasms / therapy*